Sepantronium is a DNA damaging agent that synergizes with PLK1 inhibitor volasertib

Area of Science:

• Oncology
• Cancer Biology
• Pharmacology

Background:

• Polo-like kinase 1 (PLK1) inhibitors like volasertib are investigated for cancer therapy.
• Novel combination strategies are needed to enhance anti-neoplastic effects and overcome resistance.
• Understanding drug synergy and mechanisms of action is crucial for developing effective cancer treatments.

Purpose of the Study:

• To identify novel agents that enhance the anti-cancer activity of volasertib.
• To investigate the synergistic effects of sepantronium and volasertib in non-small cell lung cancer (NSCLC) cell lines.
• To elucidate the underlying mechanisms of action for the combination therapy.

Main Methods:

• In vitro studies using NSCLC cell lines treated with volasertib and sepantronium alone and in combination.
• Analysis of cell cycle progression, protein levels (survivin, cyclin B), and DNA damage markers (phospho-γH2AX).
• Quantitative real-time PCR for gene expression analysis (CDKN1A, BAX, XRCC5) and Comet assay for DNA strand breaks.

Main Results:

• The combination of sepantronium and volasertib potently inhibited NSCLC cell growth in vitro at nanomolar concentrations.
• Combination treatment prevented adaptation to polo arrest and inhibited survivin and cyclin B accumulation.
• Sepantronium induced G1 or G2/M cell cycle arrest, DNA damage (evidenced by phospho-γH2AX and DNA strand breaks), and phosphorylation of DNA damage response proteins (ATM, ATR, CHK1, CHK2, p53).

Conclusions:

• Sepantronium acts as a DNA damaging agent that synergizes with volasertib in NSCLC.
• The observed down-regulation of survivin is likely a consequence of sepantronium-induced DNA damage.
• This combination therapy holds promise for enhancing anti-cancer efficacy in NSCLC treatment.